<DOC>
	<DOCNO>NCT02135874</DOCNO>
	<brief_summary>The goal clinical research study learn combination clofarabine , idarubicin , cytarabine , vincristine , dexamethasone , without rituximab , help control mixed phenotype acute leukemia . The safety combination also study .</brief_summary>
	<brief_title>A Phase 2 Study Clofarabine , Idarubicin , Cytarabine , Vincristine , Corticosteroids - Mixed Phenotype Acute Leukemia ( MPAL )</brief_title>
	<detailed_description>Study Drug Administration : The study drug give call cycle . Each cycle 28 day . Induction : The first cycle study drug call Induction . If doctor think need , 2 Induction cycle . During Induction cycle , receive : - Clofarabine vein 60 minute Days 1-4 . If doctor think best interest , receive Days 1-3 . - Idarubicin vein 30-60 minute Days 1-3 , 1-2 hour receive clofarabine . If doctor think best interest , receive Days 1 2 . - Cytarabine vein 2 hour Days 1-4 , 3-6 hour receive clofarabine . - Vincristine vein 15-30 minute Days 1 , 8 , 15 . - Dexamethasone vein 10-30 minute Days 1-4 15-18 . - If certain type leukemia doctor think best interest , also receive rituximab vein 4-6 hour Days 1 8 . The study staff tell receive rituximab . - If certain type leukemia ( AML FLT3-ITD ) doctor think best interest , may also receive sorafenib mouth twice day 14 day . All patient least one lumbar puncture ( spinal tap ) first cycle induction . This do check status disease give drug help prevent side effect , call intrathecal chemotherapy ( methotrexate and/or cytarabine ) . Intrathecal chemotherapy give inject chemotherapy directly cerebrospinal fluid . The standard patient receive 8 treatment . On study , receive drug 1 time unless study doctor think best interest receive additional dos . Then may receive 8 time . If doctor think best interest , dose reduce Induction . Consolidation : If disease respond study drug Induction , may receive 6 cycle study drug . This call Consolidation . During Consolidation cycle , receive : - Clofarabine vein 60 minute Days 1-3 . If doctor think best interest , receive Days 1-2 . - Idarubicin vein 30-60 minute Days 1-2 , 1-2 hour receive clofarabine . - Cytarabine vein 2 hour Days 1-3 , 3-6 hour receive clofarabine . If doctor think best interest , receive Days 1 2 . - Vincristine vein 15-30 minute Days 1 , 8 , 15 . - Dexamethasone vein 10-30 minute Days 1-4 15-18 . - If certain type leukemia doctor think best interest , also receive rituximab Consolidation Cycles 1-3 , vein 4-6 hour Days 1 8 . The study staff tell receive rituximab . - If certain type leukemia ( AML FLT3-ITD ) doctor think best interest , may also receive sorafenib mouth twice day . Study Visits : Before cycle , physical exam . Every 3-7 day , blood ( 2-3 teaspoon ) draw routine test . At end every cycle ( +/- 7 day ) , bone marrow aspirate/biopsy collect check status disease cytogenetic testing . If disease appear get good , study visit less often . Blood drawn every 7-14 day , bone marrow aspirate/biopsy study doctor think need . Length Study : You may continue receive study drug 1-2 induction cycle 6 consolidation cycle . You longer able receive study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete end-of-study visit , unless maintenance treatment discuss study doctor . End-of-Study Visit : You end-of-study visit 30 day stop receive study drug . At visit , follow test procedure perform : - You physical exam . - Blood ( 2-3 teaspoon ) draw routine test . - If study doctor think need , bone marrow aspirate and/or biopsy . - If become pregnant , urine pregnancy test . This investigational study . Clofarabine FDA approve commercially available treat acute lymphoblastic leukemia ( ALL ) child . Idarubicin cytarabine FDA approve commercially available treat acute myeloid leukemia ( AML ) . Rituximab FDA approve commercially available treat various type lymphoma leukemia . The use drug combination vincristine dexamethasone treat mixed phenotype acute leukemia investigational . The study doctor explain drug design work . Up 60 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Sign inform consent document 2 . Age 18 80 . 3 . Newly diagnose relapse MPAL , protocol , define follow : Bone marrow result interpret read Pathologist ( tissue biopsy case extramedullary disease ) : biphenotypic leukemia , bilineal leukemia , undifferentiated leukemia , mixed lineage leukemia , leukemia ambiguous lineage , T/Myeloid leukemia , B/Myeloid leukemia , diagnosis indicate presence multiple lineage within cell population . 4 . ECOG Performance Status &lt; /= 3 study entry . 5 . Adequate organ function outline ( unless due leukemia ) , Serum creatinine &lt; /= 3 mg/dL , Total bilirubin &lt; /= 2.5 mg/dL , ALT ( SGPT ) and/or AST ( SGOT ) &lt; /= 3 x ULN &lt; /= 5 x ULN relate disease 6 . Women childbearing potential must negative serum urine pregnancy test within 7 day . Women childbearing potential men must agree use contraception study entry duration active study treatment . 7 . Cardiac ejection fraction &gt; /= 40 % ( either cardiac echo MUGA scan ) . Documentation recent ( &lt; /= 6 month screen ) outside report acceptable . 8 . If newly diagnose , prior therapy hydrea and/or steroid use single two day dose cytarabine ( 3 g/m2 ) , emergency use 24 hour prior start study therapy allow . 1 . Breast feeding female 2 . Patients active , uncontrolled infection 3 . Patients active secondary malignancy eligible unless approve Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Mixed Phenotype Acute Leukemia</keyword>
	<keyword>MPAL</keyword>
	<keyword>Newly Diagnosed</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>